Byetta/Januvia Pancreatic Cancer

GSK applies for approval of diabetes drug

Reuters reports that GlaxoSmithKline, Britain’s largest pharmaceutical manufacturer, has filed for approval of a diabetes drug called albiglutide in both the United States and Europe.

The story says albiglutide is among a class of medicines that increase GLP-1, which is a hormone that stimulates insulin production from the pancreas.

A recent study found two other diabetes drugs in that class, Merck’s Januvia and Bristol-Myers Squibb’s Byetta, may double the risk of a ...

continue reading...

Expert wants more study into Byetta, Januvia pancreatitis risk

The author of a study that found two diabetes drugs may double the risk of a dangerous pancreas inflammation says his findings show a need for more research into the subject.

Bloomberg has reported on the study, which found that Merck’s diabetes drug Januvia and Bristol-Myers Squibb’s Byetta may double a user’s risk of pancreatitis.

The story says both drugs increase GLP-1, which is a hormone that stimulates insulin production from the pancreas.

Bloomberg quotes Sonal Singh, an assistant professor of medicine at ...

continue reading...

Consumers cautioned against Januvia and Byetta

A blog entry on Consumer Reports recommends that patients taking the diabetes medications Byetta or Januvia ask their doctors about possibly taking other medications.

According to Consumer Reports, people taking those two drugs may have a small but increased risk for a condition marked by stomach pain and nausea. More troubling, a new study in JAMA Internal Medicine links both drugs with an increased risk of an inflamed pancreas, called pancreatitis. The researchers noted that pancreatitis is a risk factor for ...

continue reading...

Analysis finds Byetta, Januvia linked to pancreatitis

A new analysis of insurance records published in the journal JAMA Internal Medicine adds to growing evidence of a connection between two popular diabetes drugs and a potentially deadly inflammation of the pancreas.

According to a report on the study in Bloomberg, patients hospitalized with pancreatitis — linked to cancer and kidney failure — were twice as likely to be taking Merck’s Januvia or Bristol-Myers’s Byetta than a control group of ...

continue reading...

Byetta may help with weight loss, but has side effects

A recent study shows that the type 2 diabetes drug Byetta may help severely overweight teens lose weight.

But a story in U.S. News and Word Report notes that the weight losses were modest and subjects experienced side effects including nausea and vomiting. The drug is also expensive, at $350 or more for a months’ supply.

In addition, Byetta has been linked to pancreatitis, pancreatic cancer and thyroid cancer. Another diabetes drug ...

continue reading...

Merck delays approval for new drug

According to a story in the New York Times, Merck is delaying its attempts to get approval for an experimental osteoporosis drug called odanacatib, because it is seeking additional data from a clinical trial. That announcement helped send the company’s shares down 3 percent.

The story says Merck reported that it earned $1.4 billion, or 46 cents a share, in the fourth quarter. That compares with $1.51 billion, or 49 cents ...

continue reading...
Page 9 of 13 «...7891011...»